Details for New Drug Application (NDA): 203217
✉ Email this page to a colleague
The generic ingredient in RISEDRONATE SODIUM is risedronate sodium. There is one drug master file entry for this compound. Ten suppliers are listed for this compound. Additional details are available on the risedronate sodium profile page.
Summary for 203217
| Tradename: | RISEDRONATE SODIUM |
| Applicant: | Teva Pharms Usa |
| Ingredient: | risedronate sodium |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 203217
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET, DELAYED RELEASE;ORAL | Strength | 35MG | ||||
| Approval Date: | May 18, 2015 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
